Determination of Biological Activity of Human-enriched Serum Following Chondractiv™ Plus Ingredient Ingestion

Last updated: March 20, 2025
Sponsor: Symrise Group
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Chondractiv™ Plus (Hydrolyzed chicken cartilage)

Clinical Study ID

NCT06800820
CnC2024 - ChondractivPlus
  • Ages 18-35
  • Male
  • Accepts Healthy Volunteers

Study Summary

The main objective of this study is, after collecting serum enriched with metabolites of interest resulting from the ingestion of the Chondractiv™ Plus food supplement (an hydrolyzed chicken collagen), to determine the influence of these sera enriched with circulating metabolites on the behavior of human joint cartilage cells placed in culture.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Liver function tests within reference norms.

  • Kidney function tests within reference norms.

  • Complete blood count (CBC) within reference norms.

  • C-reactive protein (CRP) within reference norms.

  • Blood pressure compatible with study requirements.

  • Non-smoker or occasional smoker (max 5 cigarettes/day or max 10 ml per week ofe-liquid with a nicotine concentration of 3 mg/ml).

  • Maximum 5 hours of intense sports per week.

  • Weight ≥ 60 kg.

  • Body Mass Index (BMI) between 20 and 28 kg/m² (exclusive).

  • Subjects who are able and willing to comply with the protocol and give theirinformed written consent.

  • Subjects affiliated with the social security.

Exclusion

Exclusion Criteria:

  • Any type of vaccination within the past month.

  • Alcohol consumption exceeding WHO standards (Sup. 3 drinks per day for men).

  • Ongoing treatment (medication, dietary supplement, or probiotic) and within the fourweeks prior to inclusion.

  • Known pathology (including seasonal).

  • Allergy to the study product

  • Individuals following a diet unsuitable for the study (e.g., vegetarian, vegan, orplant-based diets).

  • Change in eating habits within the 4 weeks prior to inclusion.

  • Medical and/or surgical history deemed incompatible with the trial by theinvestigator or their representative.

  • Persons under guardianship, curatorship, deprived of freedoms, safeguarding justice.

  • Refusal to sign the information sheet and consent

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Chondractiv™ Plus (Hydrolyzed chicken cartilage)
Phase:
Study Start date:
January 23, 2025
Estimated Completion Date:
April 02, 2025

Study Description

The clinical study will be conducted in two phases.

  1. The first phase will aim at characterizing the metabolites present in human serum after consumption of the Chondractiv™ ingredient and at determining the overall absorption peak of the tested ingredient.

  2. The second phase will involve collecting sera enriched with metabolites at the absorption peak, following the ingestion of the ingredient. Subsequently, the final objective will be to characterize the influence of these sera enriched with metabolites of interest on the behavior of human joint cartilage cell cultures.

Connect with a study center

  • Centre d'Investigation Clinique (PIC/CIC), Bâtiment 3C - 58, rue Montalembert

    Clermont-Ferrand, 63003
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.